# Tempus AI publishes multi-site validation of ECG-AF tool in Heart Rhythm journal

> Tempus AI's FDA-cleared ECG algorithm accurately predicted one-year atrial fibrillation risk in a study of over 4,000 patients aged 65 and older, published in Heart Rhythm. The peer-reviewed results bolster the company's push to convert its AI tools into reimbursable diagnostic revenue.

- Type: AI news
- Page: https://completeaitraining.com/news/tempus-ai-publishes-multi-site-validation-of-ecg-af-tool-in/
- Published: 2026-06-22
- Updated: 2026-08-10
- Author: Jeroen Erne
- Jobs: Healthcare
- Reading time: 2 min

Tempus AI's FDA-cleared ECG-AF algorithm accurately predicted one-year atrial fibrillation or flutter risk across more than 4,000 patients aged 65 and older, according to peer-reviewed results published in **Heart Rhythm**. The multi-site validation study gives the company fresh clinical ammunition as it works to convert its growing library of algorithms into reimbursable diagnostic revenue.

The study confirms the software's real-world performance outside the controlled conditions of its original regulatory submission. For a company still navigating unprofitable quarters and rich sales multiples, peer-reviewed evidence like this matters - it speaks directly to the clinical credibility payors and health systems demand before adopting AI-driven decision support tools.

#### The clinical data behind the announcement

The research drew from a cohort of over 4,000 patients, all aged 65 or older, and tested the algorithm's ability to forecast atrial fibrillation or flutter events within a one-year window. Publication in a specialty cardiology journal signals that the findings met the scrutiny of independent reviewers, which carries more weight with clinicians than a company press release alone.

Tempus AI already held FDA clearance for the ECG-AF tool. This study adds a layer of post-market evidence that the algorithm performs as intended across multiple clinical sites, not just the datasets used during the clearance process.

#### Where this fits in Tempus AI's commercial push

The ECG-AF validation arrives alongside the rollout of Tempus's next-generation Lens platform, which packages the company's multimodal AI capabilities for 19 of the top 20 biopharma clients. Together, they illustrate a deliberate strategy: turn validated algorithms into repeatable software and data contracts.

Investors watching the stock are tracking whether these tools can offset the company's high R&D and capital expenditure needs. The bullish analyst case already projects revenue reaching roughly $2.5 billion with positive earnings by 2029. Clinical validations like this one support that narrative, but the critical variable remains reimbursement. If payors move slowly on covering AI-based clinical decision support, even a growing portfolio of FDA-cleared algorithms won't guarantee commercial traction.

#### Contrasting views on the investment case

The spread between optimistic and cautious projections for Tempus AI is wide. Some analysts see a path to profitability within five years, while others point to the uncertainty around how quickly health insurers will reimburse AI-driven diagnostics. The ECG-AF study provides a concrete data point for both sides: it strengthens the clinical argument without resolving the reimbursement question.

"The new multi-site validation of its FDA-cleared ECG-AF tool adds clinical weight to its cardiovascular AI story, but does not, by itself, change that the key near term catalyst remains broader monetization of AI algorithms," the analysis noted.

#### Why this matters for healthcare professionals

For clinicians and health system leaders, the study offers independent evidence that an AI tool can stratify arrhythmia risk in older patients - a population where early detection changes treatment decisions. Peer-reviewed validation in a journal like Heart Rhythm is the type of signal many healthcare organizations look for when building the case to pilot or deploy AI-enabled diagnostics. The reimbursement landscape remains uncertain, but the clinical evidence base is getting harder to ignore.

---

This is the Markdown form of https://completeaitraining.com/news/tempus-ai-publishes-multi-site-validation-of-ecg-af-tool-in/. The whole site is mapped at https://completeaitraining.com/llms.txt.